tranexamic acid has been researched along with Recrudescence in 94 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy of topical application of the injectable form of tranexamic acid (TXA) compared with anterior nasal packing (ANP) for the treatment of epistaxis in patients taking antiplatelet drugs (aspirin, clopidogrel, or both) who presented to the emergency department (ED)." | 9.27 | Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial. ( Mousavi Jazayeri, MH; Naderi, A; Naderpour, Z; Saeedi, M; Zahed, R, 2018) |
| "Topical application of injectable form of tranexamic acid (500 mg in 5 mL) was compared with anterior nasal packing in 216 patients with anterior epistaxis presented to an ED in a randomized clinical trial." | 9.17 | A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. ( Alizadeharasi, S; Ghasemi, A; Moharamzadeh, P; Saeedi, M; Zahed, R, 2013) |
| " Overall, compared with control intervention for subarachnoid hemorrhage, tranexamic acid was associated with significantly reduced risk of rebleeding (Odd ratio [OR] =0." | 9.12 | Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis. ( Chen, H; Feng, Y, 2021) |
| "This study evaluated oral tranexamic acid as an adjunct in controlling epistaxis and preventing or reducing recurrent epistaxis." | 9.06 | Oral tranexamic acid in the management of epistaxis. ( O'Reilly, BF; White, A, 1988) |
| "A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 9.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
| "In a double-blind controlled clinical trial on 51 patients with subarachnoid hemorrhage, tranexamic acid, 4 gm per day for ten consecutive days, did not favorably affect the outcome." | 9.04 | Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. ( de Jonge, H; Endtz, LJ; Schoen, JH; van Rossum, J; Wintzen, AR, 1977) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 9.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "We found moderate-quality evidence that there is probably a reduction in the risk of re-bleeding with the use of either oral or topical tranexamic acid in addition to usual care in adult patients with epistaxis, compared to placebo with usual care." | 8.98 | Tranexamic acid for patients with nasal haemorrhage (epistaxis). ( Bellorini, J; Burton, MJ; Joseph, J; Martinez-Devesa, P, 2018) |
| "Tranexamic acid (TA) used in a variety of conditions associated with bleeding has been associated with potential thrombotic side effects such as formation of thrombi and pulmonary embolism (PE)." | 7.77 | Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. ( Krivokuca, I; Lammers, JW, 2011) |
| "In a prospective study 163 patients aged 17 years or less admitted to a children's hospital between April 1985 and December 1990 with traumatic hyphema were treated with tranexamic acid, 25 mg/kg given orally every 8 hours to a maximum of 1500 mg every 8 hours for 5 days." | 7.68 | Oral administration of tranexamic acid in the management of traumatic hyphema in children. ( Clarke, WN; Deans, R; Noël, LP, 1992) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 7.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "Tranexamic acid (TA) is an antifibrinolytic drug currently used systemically to control bleeding." | 6.87 | Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial. ( Epstein Shochet, G; Guber, A; Guber, E; Israeli-Shani, L; Shitrit, D; Wand, O, 2018) |
| "A frequent complication in patients with subarachnoid hemorrhage (SAH) is recurrent bleeding from the aneurysm." | 6.78 | Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. ( Coert, BA; Germans, MR; Post, R; Rinkel, GJ; Vandertop, WP; Verbaan, D, 2013) |
| "Tranexamic acid has been tried and has shown promising results." | 5.48 | Is topical tranexamic acid a better alternative for selected cases of anterior epistaxis management in the ED? ( Clemons, P; Hassen, GW; Kalantari, H; Kaplun, M, 2018) |
| "VTE recurrence was not significantly greater in those who received TXA (2." | 5.46 | Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. ( Abdel, MP; Amundson, AW; Larson, DR; Pagnano, MW; Sabbag, OD, 2017) |
| "Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications." | 5.31 | Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid. ( Graff, GR, 2001) |
| "Hemoptysis was only partially controlled by repeated bronchial arterial embolizations." | 5.29 | Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid. ( Culham, G; Davidson, AG; DeJong, BP; Lillquist, YP; Wong, LT, 1996) |
| "We evaluated the efficacy of topical application of the injectable form of tranexamic acid (TXA) compared with anterior nasal packing (ANP) for the treatment of epistaxis in patients taking antiplatelet drugs (aspirin, clopidogrel, or both) who presented to the emergency department (ED)." | 5.27 | Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial. ( Mousavi Jazayeri, MH; Naderi, A; Naderpour, Z; Saeedi, M; Zahed, R, 2018) |
| "Topical application of injectable form of tranexamic acid (500 mg in 5 mL) was compared with anterior nasal packing in 216 patients with anterior epistaxis presented to an ED in a randomized clinical trial." | 5.17 | A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. ( Alizadeharasi, S; Ghasemi, A; Moharamzadeh, P; Saeedi, M; Zahed, R, 2013) |
| " Overall, compared with control intervention for subarachnoid hemorrhage, tranexamic acid was associated with significantly reduced risk of rebleeding (Odd ratio [OR] =0." | 5.12 | Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis. ( Chen, H; Feng, Y, 2021) |
| " Secondary hemorrhage had no statistical association with age, gender, oral prednisolone, size of hyphema, and retinal damage." | 5.09 | An analysis of risk for secondary hemorrhage in traumatic hyphema. ( Jahadi, HR; Rahmani, B; Rajaeefard, A, 1999) |
| "This study evaluated oral tranexamic acid as an adjunct in controlling epistaxis and preventing or reducing recurrent epistaxis." | 5.06 | Oral tranexamic acid in the management of epistaxis. ( O'Reilly, BF; White, A, 1988) |
| "One hundred patients with a verified subarachnoid haemorrhage were studied in a double blind, placebo-controlled trial at a single centre to determine the value and relative risks of tranexamic acid (TXA) in the management of ruptured intracranial aneurysms." | 5.06 | Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. ( Hitchcock, ER; Meyer, CH; Tsementzis, SA, 1990) |
| "Seventy patients with subarachnoid haemorrhage due to ruptured intracranial aneurysms were managed by delayed intervention (third week) along with the prescription of antifibrinolytic drugs (tranexamic acid 6 g/daily)." | 5.06 | [Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy]. ( Chabannes, J; Chazal, J; Commun, C; Irthum, B; Janny, P, 1986) |
| "A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 5.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
| "We enrolled 479 patients with subarachnoid hemorrhage in a multicenter, randomized, double-blind, placebo-controlled trial to determine whether treatment with the antifibrinolytic agent tranexamic acid improves outcome by preventing rebleeding." | 5.05 | Antifibrinolytic treatment in subarachnoid hemorrhage. ( Cheah, F; Hijdra, A; Lindsay, KW; Muizelaar, JP; Murray, GD; Schannong, M; Teasdale, GM; van Crevel, H; van Gijn, J; Vermeulen, M, 1984) |
| "In a double-blind controlled clinical trial on 51 patients with subarachnoid hemorrhage, tranexamic acid, 4 gm per day for ten consecutive days, did not favorably affect the outcome." | 5.04 | Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. ( de Jonge, H; Endtz, LJ; Schoen, JH; van Rossum, J; Wintzen, AR, 1977) |
| "The outcome of treatment with an antifibrinolytic agent (tranexamic acid) for six weeks after rupture of an intracranial aneurysm was assessed in a randomised controlled trial." | 5.04 | Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms? ( Maurice-Williams, RS, 1978) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 5.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "We found moderate-quality evidence that there is probably a reduction in the risk of re-bleeding with the use of either oral or topical tranexamic acid in addition to usual care in adult patients with epistaxis, compared to placebo with usual care." | 4.98 | Tranexamic acid for patients with nasal haemorrhage (epistaxis). ( Bellorini, J; Burton, MJ; Joseph, J; Martinez-Devesa, P, 2018) |
| " In a few small studies, thalidomide was shown to consistently improve severity and frequency of epistaxis and improve hemoglobin concentrations while decreasing the need for transfusion." | 4.98 | Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. ( Clark, C; Halderman, AA; Invernizzi, R; Marple, BF; Poetker, DM; Reh, DD; Ryan, MW; Sindwani, R, 2018) |
| "Tranexamic acid (TA) used in a variety of conditions associated with bleeding has been associated with potential thrombotic side effects such as formation of thrombi and pulmonary embolism (PE)." | 3.77 | Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. ( Krivokuca, I; Lammers, JW, 2011) |
| "In a prospective study 163 patients aged 17 years or less admitted to a children's hospital between April 1985 and December 1990 with traumatic hyphema were treated with tranexamic acid, 25 mg/kg given orally every 8 hours to a maximum of 1500 mg every 8 hours for 5 days." | 3.68 | Oral administration of tranexamic acid in the management of traumatic hyphema in children. ( Clarke, WN; Deans, R; Noël, LP, 1992) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 3.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "Three hundred forty children with nonperforating traumatic hyphema were examined to verify or refute the possible protective action of the antifibrinolytic agent, tranexamic acid, against rebleeding." | 3.67 | Management of traumatic hyphema in children. An analysis of 340 cases. ( Ranta-Kemppainen, L; Tarkkanen, A; Uusitalo, RJ, 1988) |
| " However, no clear consensus on the dosing and duration of maintenance doses of TXA therapy in melasma exists." | 3.30 | A randomized, open-label study to compare two different dosing regimens of oral tranexamic acid in treatment of moderate to severe facial melasma. ( Bhattacharjee, R; Bishnoi, A; Hanumanthu, V; Kumar, A; Kumaran, MS; Parsad, D; Thakur, V; Vinay, K, 2023) |
| "Tranexamic acid (TXA) has been hypothesized as an oral agent to avoid CSDH progression and/or recurrence." | 3.30 | Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial. ( de Freitas, PVV; de Oliveira, MF; de Paula, MVCT; Melo, MM; Pahl, FH; Ribeiro, BDC; Rotta, JM, 2023) |
| "As relapses are frequent on discontinuation, a minimum effective dose of TXA that can be used safely for long time remains unknown." | 3.01 | Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study. ( Chauhan, PS; Chowdhary, B; Kumar, P; Mahajan, VK; Mehta, KS; Sharma, A; Sharma, V; Vashist, S, 2021) |
| "A total of 297 patients with chronic subdural hematoma underwent initial burr hole surgery at our hospital from April 2014 to March 2018." | 2.94 | Prospective Study on the Efficacy of Orally Administered Tranexamic Acid and Goreisan for the Prevention of Recurrence After Chronic Subdural Hematoma Burr Hole Surgery. ( Natori, Y; Yamada, T, 2020) |
| " Secondary endpoints were comparison of post-operative volumes between the treatment arms and safety evaluation of the dosing regime." | 2.94 | An open label randomized trial to assess the efficacy of tranexamic acid in reducing post-operative recurrence of chronic subdural haemorrhage. ( Khong, WXL; King, NKK; Ng, WH; Ong, JCL; Qiu, L; Saffari, SE; See, AA; Wan, KR, 2020) |
| "Tranexamic acid (TA) is an antifibrinolytic drug currently used systemically to control bleeding." | 2.87 | Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial. ( Epstein Shochet, G; Guber, A; Guber, E; Israeli-Shani, L; Shitrit, D; Wand, O, 2018) |
| "Tranexamic acid has been shown to reduce the need for blood transfusion in surgical patients and to reduce mortality in bleeding trauma patients, with no apparent increase in thromboembolic events." | 2.79 | HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. ( Coats, T; Edwards, P; Gilmore, I; Jairath, V; Ker, K; Manno, D; Roberts, I; Shakur, H; Stanworth, S; Veitch, A, 2014) |
| "A frequent complication in patients with subarachnoid hemorrhage (SAH) is recurrent bleeding from the aneurysm." | 2.78 | Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. ( Coert, BA; Germans, MR; Post, R; Rinkel, GJ; Vandertop, WP; Verbaan, D, 2013) |
| "The bleeding was effectively controlled within 1 to 48 h in five of nine bleeding episodes." | 2.69 | Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. ( Angchaisuksiri, P; Chuansumrit, A; Hathirat, P; Isarangkura, P; Jorgensen, LN; Sriudomporn, N; Tanpowpong, K, 2000) |
| "Tranexamic acid treatment was without side effects and was given in standard doses until closure of the aneurysm or alternatively up to three days after the initial bleeding." | 2.43 | ["Ultra-early" antifibrinolytic treatment of subarachnoidal bleeding with tranexamic acid]. ( Astrup, J, 2006) |
| "Gingival hemorrhage is recognized as a symptom of MDS, a rare group of potentially fatal hematological disorders, but it has not previously been documented as a presenting sign." | 2.40 | Gingival hemorrhage, myelodysplastic syndromes, and acute myeloid leukemia. A case report. ( Chapple, IL; Murray, JA; Saxby, MS, 1999) |
| "Hereditary angioneurotic edema (HAE) is an autosomal dominant disease caused by a deficiency of a complement regulatory protein, the C1INH." | 2.38 | [Clinical contribution to the problem of correlations between hereditary angioneurotic edema and pregnancy]. ( Barrile, A; Bonanno, D; Crisafi, A; Ferlazzo, B; Ferrari, U; Quattrocchi, P; Sorge, R, 1990) |
| "The conservative management of Chronic subdural hematoma (CSDH) is controversial." | 1.56 | The Outcome of Medical Management of Chronic Subdural Hematoma with Tranexamic Acid - A Prospective Observational Study. ( Asher, P; Kutty, RK; Leela, SK; Peethambaran, A; Prabhakar, RB; Sivanandapanicker, JL; Sreemathyamma, SB, 2020) |
| "Tranexamic acid has been tried and has shown promising results." | 1.48 | Is topical tranexamic acid a better alternative for selected cases of anterior epistaxis management in the ED? ( Clemons, P; Hassen, GW; Kalantari, H; Kaplun, M, 2018) |
| "VTE recurrence was not significantly greater in those who received TXA (2." | 1.46 | Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. ( Abdel, MP; Amundson, AW; Larson, DR; Pagnano, MW; Sabbag, OD, 2017) |
| "BACKGROUND Chronic subdural hematoma (CSDH) is a common neurosurgical condition that is treated using a cranial burr hole evacuation procedure, but recurrence is common." | 1.46 | A Case of Tranexamic Acid as Adjunctive Treatment for Chronic Subdural Hematoma with Multiple Recurrences. ( Anker-Møller, T; Hvas, AM; Mikkelsen, R; Sunde, N, 2017) |
| "All patients had recurrence identified on subsequent imaging." | 1.43 | Tranexamic Acid for Recurring Subdural Hematomas Following Surgical Evacuation: A Clinical Case Series. ( Hutchins, L; Stary, JM; Vega, RA, 2016) |
| "Melasma is a common pigmentary disorder among Asians and treatment is challenging." | 1.43 | Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. ( Goh, CL; Lee, HC; Thng, TG, 2016) |
| "Tranexamic acid (TXA) has a high clinical value for the treatment of bleeding due to fibrinolysis." | 1.42 | Warfarin-related recurrent knee haemarthrosis treated with arterial embolisation and intra-articular injection of tranexamic acid. ( Kunugiza, Y; Mikami, K; Nakamura, Y; Suzuki, S, 2015) |
| "C1 Inhibitor deficiency is a rare disorder, characterised by recurrent angio-oedema of skin, upper respiratory and gastrointestinal tracts." | 1.39 | Recurrent angio-oedema--three cases of C1 inhibitor deficiency. ( Chandini, R; Neeraj, M; Philip, A; Shajith, S; Soopy, K; Thulseedharan, NK, 2013) |
| "Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic telangiectasia (HHT)." | 1.34 | Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. ( Bernabéu, C; Botella, LM; Fernandez-L, A; Garrido-Martin, EM; Morales-Angulo, C; Perez-Molino, A; Ramirez, JR; Sanz-Rodriguez, F; Zarrabeitia, R, 2007) |
| "Hereditary angioneurotic edema results from the deficiency of C1-esterase inhibitor." | 1.31 | [Hereditary angioneurotic edema in children]. ( Farkas, H; Füst, G; Harmat, G; Varga, L; Visy, B, 2000) |
| "Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications." | 1.31 | Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid. ( Graff, GR, 2001) |
| "A patient with von Willebrand's disease had recurrent gastrointestinal bleeding from angiodysplasia, with inadequate response to von Willebrand factor substitution, medical and endoscopic treatment, and resection of affected bowel." | 1.31 | Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. ( Meijer, K; Peters, FT; van der Meer, J, 2001) |
| "Cerebral ischemia was treated with vigorous plasma volume expansion under intermittent monitoring of pulmonary wedge pressure, cardiac output, and arterial blood pressure, aiming for a hematocrit of 0." | 1.30 | Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. ( Avezaat, CJ; Bijvoet, HW; Hasan, D; Vermeij, FH, 1998) |
| "Hemoptysis was only partially controlled by repeated bronchial arterial embolizations." | 1.29 | Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid. ( Culham, G; Davidson, AG; DeJong, BP; Lillquist, YP; Wong, LT, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (32.98) | 18.7374 |
| 1990's | 12 (12.77) | 18.2507 |
| 2000's | 14 (14.89) | 29.6817 |
| 2010's | 27 (28.72) | 24.3611 |
| 2020's | 10 (10.64) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Y | 1 |
| Chen, H | 1 |
| Shibahashi, K | 1 |
| Ohbe, H | 1 |
| Yasunaga, H | 1 |
| Bhattacharjee, R | 1 |
| Hanumanthu, V | 1 |
| Thakur, V | 1 |
| Bishnoi, A | 1 |
| Vinay, K | 1 |
| Kumar, A | 1 |
| Parsad, D | 1 |
| Kumaran, MS | 1 |
| de Paula, MVCT | 1 |
| Ribeiro, BDC | 1 |
| Melo, MM | 1 |
| de Freitas, PVV | 1 |
| Pahl, FH | 1 |
| de Oliveira, MF | 1 |
| Rotta, JM | 1 |
| Yamada, T | 1 |
| Natori, Y | 1 |
| Post, R | 2 |
| Germans, MR | 2 |
| Coert, BA | 2 |
| Rinkel, GJE | 1 |
| Vandertop, WP | 2 |
| Verbaan, D | 2 |
| Chowdhary, B | 1 |
| Mahajan, VK | 1 |
| Mehta, KS | 1 |
| Chauhan, PS | 1 |
| Sharma, V | 1 |
| Sharma, A | 1 |
| Vashist, S | 1 |
| Kumar, P | 1 |
| Kutty, RK | 1 |
| Leela, SK | 1 |
| Sreemathyamma, SB | 1 |
| Sivanandapanicker, JL | 1 |
| Asher, P | 1 |
| Peethambaran, A | 1 |
| Prabhakar, RB | 1 |
| Wan, KR | 1 |
| Qiu, L | 1 |
| Saffari, SE | 1 |
| Khong, WXL | 1 |
| Ong, JCL | 1 |
| See, AA | 1 |
| Ng, WH | 1 |
| King, NKK | 1 |
| Panda, PK | 1 |
| Sharawat, IK | 1 |
| Anker-Møller, T | 2 |
| Troldborg, A | 1 |
| Sunde, N | 2 |
| Hvas, AM | 2 |
| Mikkelsen, R | 1 |
| Zahed, R | 2 |
| Mousavi Jazayeri, MH | 1 |
| Naderi, A | 1 |
| Naderpour, Z | 1 |
| Saeedi, M | 2 |
| Hassen, GW | 1 |
| Clemons, P | 1 |
| Kaplun, M | 1 |
| Kalantari, H | 1 |
| Halderman, AA | 1 |
| Ryan, MW | 1 |
| Clark, C | 1 |
| Sindwani, R | 1 |
| Reh, DD | 1 |
| Poetker, DM | 1 |
| Invernizzi, R | 1 |
| Marple, BF | 1 |
| Wand, O | 1 |
| Guber, E | 1 |
| Guber, A | 1 |
| Epstein Shochet, G | 1 |
| Israeli-Shani, L | 1 |
| Shitrit, D | 1 |
| Joseph, J | 1 |
| Martinez-Devesa, P | 1 |
| Bellorini, J | 1 |
| Burton, MJ | 1 |
| Bistervels, IM | 1 |
| Scheres, LJJ | 1 |
| Hamulyák, EN | 1 |
| Middeldorp, S | 1 |
| Otrock, ZK | 1 |
| Degheili, JA | 1 |
| Sibai, H | 1 |
| Salem, ZM | 1 |
| Rinkel, GJ | 1 |
| Moharamzadeh, P | 1 |
| Alizadeharasi, S | 1 |
| Ghasemi, A | 1 |
| Philip, A | 1 |
| Neeraj, M | 1 |
| Soopy, K | 1 |
| Shajith, S | 1 |
| Chandini, R | 1 |
| Thulseedharan, NK | 1 |
| Fischer, Q | 1 |
| Huisse, MG | 1 |
| Voiriot, G | 1 |
| Caron, C | 1 |
| Lepage, L | 1 |
| Dilly, MP | 1 |
| Nataf, P | 1 |
| Ajzenberg, N | 1 |
| Kirsch, M | 1 |
| Roberts, I | 1 |
| Coats, T | 1 |
| Edwards, P | 1 |
| Gilmore, I | 1 |
| Jairath, V | 1 |
| Ker, K | 1 |
| Manno, D | 1 |
| Shakur, H | 1 |
| Stanworth, S | 1 |
| Veitch, A | 1 |
| Vincent, D | 1 |
| Ponard, D | 2 |
| Fiorella, S | 1 |
| Drouet, C | 2 |
| Kunugiza, Y | 1 |
| Nakamura, Y | 1 |
| Mikami, K | 1 |
| Suzuki, S | 1 |
| Flores, S | 1 |
| Avilés, C | 1 |
| Rada, G | 1 |
| Tutchenko, MI | 1 |
| Rudyk, DV | 1 |
| Iskra, NI | 1 |
| Trofimenko, SP | 1 |
| Shchur, IV | 1 |
| Iorio-Morin, C | 1 |
| Blanchard, J | 1 |
| Richer, M | 1 |
| Mathieu, D | 1 |
| Lee, HC | 1 |
| Thng, TG | 1 |
| Goh, CL | 1 |
| Stary, JM | 1 |
| Hutchins, L | 1 |
| Vega, RA | 1 |
| Sabbag, OD | 1 |
| Abdel, MP | 1 |
| Amundson, AW | 1 |
| Larson, DR | 1 |
| Pagnano, MW | 1 |
| Albiani, DA | 1 |
| Hodge, WG | 1 |
| Pan, YI | 1 |
| Urton, TE | 1 |
| Clarke, WN | 2 |
| Edalati, K | 1 |
| Roesch, MT | 1 |
| Buchanan, ML | 1 |
| Teeter, M | 1 |
| Maberley, DA | 1 |
| Almadi, M | 1 |
| Ghali, PM | 1 |
| Constantin, A | 1 |
| Galipeau, J | 1 |
| Szilagyi, A | 1 |
| Krivokuca, I | 1 |
| Lammers, JW | 1 |
| Yadav, SP | 1 |
| Sachdeva, A | 1 |
| Bhat, S | 1 |
| Katewa, S | 1 |
| Larsen, CC | 1 |
| Eskesen, V | 1 |
| Hauerberg, J | 1 |
| Olesen, C | 1 |
| Romner, B | 1 |
| Astrup, J | 2 |
| Zanichelli, A | 1 |
| Vacchini, R | 1 |
| Badini, M | 1 |
| Penna, V | 1 |
| Cicardi, M | 2 |
| Fernández-Mondéjar, E | 1 |
| Guerrero-López, F | 1 |
| Yasui, H | 1 |
| Adachi, Y | 1 |
| Minami, T | 1 |
| Ishida, T | 1 |
| Kato, Y | 1 |
| Imai, K | 1 |
| Aydinok, Y | 1 |
| Egemen, A | 1 |
| Balkan, C | 1 |
| Fernandez-L, A | 1 |
| Garrido-Martin, EM | 1 |
| Sanz-Rodriguez, F | 1 |
| Ramirez, JR | 1 |
| Morales-Angulo, C | 1 |
| Zarrabeitia, R | 1 |
| Perez-Molino, A | 1 |
| Bernabéu, C | 1 |
| Botella, LM | 1 |
| Bouillet, L | 1 |
| Rousset, H | 1 |
| Cichon, S | 1 |
| Adamsen, S | 1 |
| de Muckadell, OB | 1 |
| Vangsted, P | 1 |
| Nielsen, PJ | 1 |
| Vermeulen, M | 2 |
| Lindsay, KW | 2 |
| Murray, GD | 2 |
| Cheah, F | 1 |
| Hijdra, A | 1 |
| Muizelaar, JP | 1 |
| Schannong, M | 3 |
| Teasdale, GM | 1 |
| van Crevel, H | 1 |
| van Gijn, J | 2 |
| Fodstad, H | 2 |
| Forssell, A | 1 |
| Liliequist, B | 2 |
| Chowdhary, UM | 1 |
| Sayed, K | 1 |
| Maurice-Williams, RS | 3 |
| Varnek, L | 1 |
| Dalsgaard, C | 1 |
| Hansen, A | 1 |
| Klie, F | 1 |
| Gordon, YB | 1 |
| Sykes, A | 1 |
| Alvarez Garijo, JA | 1 |
| Vilches, JJ | 1 |
| Aznar, JA | 1 |
| Gelmers, HJ | 1 |
| Sjølie, AK | 1 |
| Mortensen, KK | 1 |
| Adams, HP | 1 |
| Nibbelink, DW | 1 |
| Torner, JC | 2 |
| Sahs, AL | 1 |
| Katschinski, B | 1 |
| Logan, R | 1 |
| Davies, J | 1 |
| Faulkner, G | 1 |
| Pearson, J | 1 |
| Langman, M | 1 |
| Wong, LT | 1 |
| Lillquist, YP | 1 |
| Culham, G | 1 |
| DeJong, BP | 1 |
| Davidson, AG | 1 |
| Chang, AB | 1 |
| Ditchfield, M | 1 |
| Robinson, PJ | 1 |
| Robertson, CF | 1 |
| Castelli, R | 1 |
| Gardinali, M | 1 |
| Zingale, LC | 1 |
| Savi, C | 1 |
| Munari, M | 1 |
| Agostoni, A | 1 |
| Schisano, G | 1 |
| Nina, P | 1 |
| Vermeij, FH | 1 |
| Hasan, D | 2 |
| Bijvoet, HW | 1 |
| Avezaat, CJ | 1 |
| Rahmani, B | 1 |
| Jahadi, HR | 1 |
| Rajaeefard, A | 1 |
| Baerlocher, GM | 1 |
| Leoncini-Franscini, L | 1 |
| Wuillemin, WA | 1 |
| Furlan, M | 1 |
| Chapple, IL | 1 |
| Saxby, MS | 1 |
| Murray, JA | 1 |
| Chuansumrit, A | 1 |
| Isarangkura, P | 1 |
| Angchaisuksiri, P | 1 |
| Sriudomporn, N | 1 |
| Tanpowpong, K | 1 |
| Hathirat, P | 1 |
| Jorgensen, LN | 1 |
| Farkas, H | 1 |
| Harmat, G | 1 |
| Füst, G | 1 |
| Varga, L | 1 |
| Visy, B | 1 |
| Graff, GR | 1 |
| Meijer, K | 1 |
| Peters, FT | 1 |
| van der Meer, J | 1 |
| Hawkey, GM | 1 |
| Cole, AT | 1 |
| McIntyre, AS | 1 |
| Long, RG | 1 |
| Hawkey, CJ | 1 |
| Thulin, CA | 1 |
| van Rossum, J | 1 |
| Wintzen, AR | 1 |
| Endtz, LJ | 1 |
| Schoen, JH | 1 |
| de Jonge, H | 1 |
| Astedt, B | 1 |
| Nilsson, IM | 1 |
| Thompson, RA | 1 |
| Felix-Davies, DD | 1 |
| Tovi, D | 1 |
| Tamaki, N | 1 |
| Kusunoki, T | 1 |
| Oi, S | 1 |
| Taomoto, K | 1 |
| Matsumoto, S | 1 |
| Deans, R | 1 |
| Noël, LP | 1 |
| Ferlazzo, B | 1 |
| Barrile, A | 1 |
| Bonanno, D | 1 |
| Crisafi, A | 1 |
| Ferrari, U | 1 |
| Quattrocchi, P | 1 |
| Sorge, R | 1 |
| Tsementzis, SA | 1 |
| Hitchcock, ER | 1 |
| Meyer, CH | 1 |
| Spallone, A | 1 |
| Pastore, FS | 1 |
| Rizzo, A | 1 |
| Guidetti, B | 1 |
| Wijdicks, EF | 1 |
| Brouwers, PJ | 1 |
| Hatfield, R | 1 |
| Langman, MJ | 1 |
| White, A | 1 |
| O'Reilly, BF | 1 |
| Fukuchi, S | 1 |
| Sakai, M | 1 |
| Miyake, T | 1 |
| Uusitalo, RJ | 1 |
| Ranta-Kemppainen, L | 1 |
| Tarkkanen, A | 1 |
| Kassell, NF | 1 |
| Haley, EC | 1 |
| von Holstein, CC | 1 |
| Eriksson, SB | 1 |
| Källén, R | 1 |
| Irthum, B | 1 |
| Chazal, J | 1 |
| Commun, C | 1 |
| Chabannes, J | 1 |
| Janny, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. A Prospective, Randomized, Multicenter Study.[NCT02684812] | Phase 2/Phase 3 | 955 participants (Actual) | Interventional | 2012-07-16 | Completed | ||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| [NCT01496196] | Phase 3 | 100 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| Randomized Study on the Topical Application of Tranexamic Acid to Wound Bed for Hemostasis in the Setting Granulating Wounds Following Mohs Micrographic Surgery[NCT04541303] | Early Phase 1 | 62 participants (Anticipated) | Interventional | 2020-10-08 | Recruiting | ||
| Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department[NCT02930941] | Phase 4 | 35 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Terminate due to slow enrollment rate.) | ||
| Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial[NCT01658124] | Phase 3 | 12,009 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Tranexamic Acid in Chronic Subdural Hematomas[NCT02568124] | Phase 2/Phase 3 | 130 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans[NCT04233749] | Phase 2 | 5 participants (Anticipated) | Interventional | 2020-03-17 | Recruiting | ||
| Tissue-resident Memory T Cells Expression in Melasma[NCT05698342] | 20 participants (Actual) | Observational | 2021-07-01 | Completed | |||
| Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot[NCT02536989] | Phase 4 | 40 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial[NCT02903017] | Phase 4 | 114 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of stay was defined as time from enrollment in study to discharge from the emergency department (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 268 |
| NS Group | 346 |
The number of participants with re-bleeding at 24 Hours was evaluated during follow up phone call (NCT02930941)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 3 |
| NS Group | 9 |
The number of participants with re-bleeding at one week was evaluated during the follow-up phone call (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 2 |
| NS Group | 6 |
Patient reported thromboembolic events during follow-up phone calls at 24 hours and at one week (NCT02930941)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| TXA Group | 0 |
| NS Group | 0 |
Time to control of bleeding was defined as the time from the start of enrollment and direct pressure and administration of study drug to the resolution of bleeding (NCT02930941)
Timeframe: During emergency department (ED) visit
| Intervention | minutes (Median) |
|---|---|
| TXA Group | 64 |
| NS Group | 42 |
Patient-reported drug-related adverse events during ED visit (NCT02930941)
Timeframe: during emergency department (ED) visit
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Nasal burning | Nasal irritation | Unpleasant taste | |
| NS Group | 0 | 0 | 0 |
| TXA Group | 2 | 0 | 1 |
11 reviews available for tranexamic acid and Recrudescence
| Article | Year |
|---|---|
Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Humans; Recurrence; Secondary Prevention; Subarachnoid Hemorrhage; Tranexam | 2021 |
Evidence for the Use of Tranexamic Acid in Subarachnoid and Subdural Hemorrhage: A Systematic Review.
Topics: Antifibrinolytic Agents; Hematoma, Subdural; Humans; Recurrence; Subarachnoid Hemorrhage; Survival R | 2017 |
Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Epistaxis; Estriol; Estrogen | 2018 |
Tranexamic acid for patients with nasal haemorrhage (epistaxis).
Topics: Administration, Oral; Administration, Topical; Antifibrinolytic Agents; Blood Transfusion; Epinephri | 2018 |
Sex matters: Practice 5P's when treating young women with venous thromboembolism.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Combined; Disease Susceptibility; Female; Heparin, Low- | 2019 |
Is tranexamic acid effective for acute upper gastrointestinal bleeding?
Topics: Acute Disease; Antifibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Randomized Controlled T | 2015 |
Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Angiography; Animals; Antifibrinol | 2009 |
["Ultra-early" antifibrinolytic treatment of subarachnoidal bleeding with tranexamic acid].
Topics: Aneurysm, Ruptured; Antifibrinolytic Agents; Aortic Aneurysm; Denmark; Early Diagnosis; Emergencies; | 2006 |
[Treatment of bleeding gastroduodenal ulcer].
Topics: Antacids; Antifibrinolytic Agents; Duodenal Ulcer; Duodenoscopy; Embolization, Therapeutic; Epinephr | 2007 |
Gingival hemorrhage, myelodysplastic syndromes, and acute myeloid leukemia. A case report.
Topics: Acute Disease; Biopsy, Needle; Bone Marrow Cells; Chronic Disease; Diagnosis, Differential; Gingival | 1999 |
[Clinical contribution to the problem of correlations between hereditary angioneurotic edema and pregnancy].
Topics: Adult; Angioedema; Contraindications; Female; Humans; Infant, Newborn; Pedigree; Pregnancy; Pregnanc | 1990 |
28 trials available for tranexamic acid and Recrudescence
| Article | Year |
|---|---|
A randomized, open-label study to compare two different dosing regimens of oral tranexamic acid in treatment of moderate to severe facial melasma.
Topics: Administration, Oral; Adult; Humans; Melanosis; Middle Aged; Quality of Life; Recurrence; Tranexamic | 2023 |
Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial.
Topics: Aged; Drainage; Hematoma, Subdural, Chronic; Humans; Postoperative Complications; Postoperative Peri | 2023 |
Prospective Study on the Efficacy of Orally Administered Tranexamic Acid and Goreisan for the Prevention of Recurrence After Chronic Subdural Hematoma Burr Hole Surgery.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Drugs, Chinese Herbal; Female; Follow-Up Studie | 2020 |
Update of the ULtra-early TRranexamic Acid after Subarachnoid Hemorrhage (ULTRA) trial: statistical analysis plan.
Topics: Adult; Antifibrinolytic Agents; Cerebral Infarction; Clinical Trials, Phase II as Topic; Clinical Tr | 2020 |
Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study.
Topics: Administration, Oral; Adolescent; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; | 2021 |
An open label randomized trial to assess the efficacy of tranexamic acid in reducing post-operative recurrence of chronic subdural haemorrhage.
Topics: Aged; Antifibrinolytic Agents; Female; Hematoma, Subdural, Chronic; Humans; Male; Neurosurgical Proc | 2020 |
Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Endotamponade; Epistaxis; Female; Humans; Ma | 2018 |
Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Monitoring; Fe | 2018 |
Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Monitoring; Fe | 2018 |
Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Monitoring; Fe | 2018 |
Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug Monitoring; Fe | 2018 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Disability Evaluation; Drug Administration Schedule; Ea | 2013 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
Topics: Administration, Intranasal; Antifibrinolytic Agents; Emergency Service, Hospital; Epistaxis; Female; | 2013 |
HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial.
Topics: Antifibrinolytic Agents; Blood Transfusion; Clinical Protocols; Double-Blind Method; Drug Administra | 2014 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial.
Topics: Antifibrinolytic Agents; Clinical Protocols; Cognition; Double-Blind Method; Hematoma, Subdural, Chr | 2016 |
Tranexamic acid and traumatic hyphaema. A prospective study.
Topics: Adolescent; Adult; Aged; Bed Rest; Child; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fem | 1983 |
Antifibrinolytic treatment in subarachnoid hemorrhage.
Topics: Cerebral Angiography; Cerebral Infarction; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Do | 1984 |
Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial.
Topics: Adult; Aged; Brain Ischemia; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; | 1981 |
Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Clinical Trials as Topic; Cyclohexanecarboxyli | 1981 |
Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid.
Topics: Adult; Aged; Cyclohexanecarboxylic Acids; Female; Humans; Male; Middle Aged; Recurrence; Subarachnoi | 1980 |
Prognostic factors in upper gastrointestinal bleeding.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cimetidine; Duodenal Ulcer; Female | 1994 |
An analysis of risk for secondary hemorrhage in traumatic hyphema.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifibrinolytic Agents; Child; Child, Preschool; Eye | 1999 |
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Child, Preschool; Disease Management; Fact | 2000 |
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Blood Transfusi | 2001 |
Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Recurrence; Ru | 1978 |
Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
Topics: Adult; Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Constriction, Pathologic; Cyclohexan | 1978 |
Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial.
Topics: Aged; Cerebral Angiography; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Meth | 1977 |
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.
Topics: Adult; Aged; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Cyclohexanecarbo | 1990 |
Oral tranexamic acid in the management of epistaxis.
Topics: Administration, Oral; Aged; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double-Blind Meth | 1988 |
Tranexamic acid in gastric and duodenal bleeding.
Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Cyclohexanecarboxylic Acids; Double-Blind Method; | 1987 |
[Prospective trial of treating aneurysmal meningeal hemorrhage by delayed operation under cover of antifibrinolytic therapy].
Topics: Adult; Aged; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; Intracranial Ane | 1986 |
55 other studies available for tranexamic acid and Recrudescence
| Article | Year |
|---|---|
Adjuvant oral tranexamic acid and reoperation after burr hole surgery in patients with chronic subdural hematoma: propensity score-matched analysis using a nationwide inpatient database.
Topics: Drainage; Hematoma, Subdural, Chronic; Humans; Inpatients; Propensity Score; Recurrence; Reoperation | 2023 |
The Outcome of Medical Management of Chronic Subdural Hematoma with Tranexamic Acid - A Prospective Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Conservative Treatment; Female; Hematoma, S | 2020 |
Preventive role of tranexamic acid in post-operative recurrence of chronic subdural haemorrhage: Do we have sufficient evidence?
Topics: Antifibrinolytic Agents; Hematoma, Subdural, Chronic; Humans; Postoperative Period; Recurrence; Tran | 2021 |
A Case of Tranexamic Acid as Adjunctive Treatment for Chronic Subdural Hematoma with Multiple Recurrences.
Topics: Antifibrinolytic Agents; Combined Modality Therapy; Craniotomy; Hematoma, Subdural, Chronic; Humans; | 2017 |
Is topical tranexamic acid a better alternative for selected cases of anterior epistaxis management in the ED?
Topics: Administration, Intranasal; Administration, Topical; Antifibrinolytic Agents; Emergency Service, Hos | 2018 |
Recurrent jejunal bleeding due to angiodysplasia in a Bernard-Soulier patient.
Topics: Aged; Angiodysplasia; Antifibrinolytic Agents; Bernard-Soulier Syndrome; Blood Vessels; Female; Gast | 2013 |
Recurrent angio-oedema--three cases of C1 inhibitor deficiency.
Topics: Abdominal Pain; Adolescent; Adult; Angioedemas, Hereditary; Antifibrinolytic Agents; Complement C1 I | 2013 |
Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients?
Topics: Aged; Combined Modality Therapy; Deamino Arginine Vasopressin; Embolization, Therapeutic; Erythrocyt | 2015 |
Benefits of hydroxychloroquine in the treatment of a patient with angioedema due to acquired C1 inhibitor deficiency.
Topics: Aged; Angioedema; Angioedemas, Hereditary; Antibodies, Blocking; Autoantibodies; Autoimmunity; Compl | 2015 |
Warfarin-related recurrent knee haemarthrosis treated with arterial embolisation and intra-articular injection of tranexamic acid.
Topics: Anticoagulants; Antifibrinolytic Agents; Embolization, Therapeutic; Female; Hemarthrosis; Humans; In | 2015 |
[MODERN VIEW ON INTENSIVE THERAPY OF GASTRO-INTESTINAL HEMORRHAGE].
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Female; Gastrointestinal Agents; Gastrointestinal | 2015 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.
Topics: Administration, Oral; Adult; Asian People; Dermatologic Agents; Facial Dermatoses; Female; Gastroint | 2016 |
Tranexamic Acid for Recurring Subdural Hematomas Following Surgical Evacuation: A Clinical Case Series.
Topics: Adult; Aged, 80 and over; Antifibrinolytic Agents; Brain; Craniotomy; Female; Hematoma, Subdural; Hu | 2016 |
Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthropl | 2017 |
Tranexamic acid in the treatment of pediatric traumatic hyphema.
Topics: Antifibrinolytic Agents; Child; Drug Therapy, Combination; Eye Injuries; Female; Glucocorticoids; Hu | 2008 |
Central serous chorioretinopathy and idiopathic nonhistaminergic angioedema.
Topics: Adult; Angioedema; Antifibrinolytic Agents; Capillary Permeability; Choroid; Fluorescein Angiography | 2009 |
Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid.
Topics: Antifibrinolytic Agents; Chronic Disease; Female; Hemoptysis; Humans; Middle Aged; Pulmonary Embolis | 2011 |
Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion.
Topics: beta-Thalassemia; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Delayed Graft F | 2010 |
Considerable delay in diagnosis and acute management of subarachnoid haemorrhage.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Antifibrinolytic Agents; Delayed Dia | 2010 |
Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androgens; Child; Child, Preschool; Complement C1 Inhibi | 2011 |
[Secondary prevention in trauma pathology. Is there an influence of commercial interests on evidence implementation?].
Topics: Accident Prevention; Commerce; Decontamination; Diffusion of Innovation; Drug Utilization; Evidence- | 2012 |
Combination therapy of DDAVP and conjugated estrogens for a recurrent large subcutaneous hematoma in Ehlers-Danlos syndrome.
Topics: Adrenochrome; Adult; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Dru | 2003 |
Menorrhagia due to abnormalities of the platelet function: evaluation of two young patients.
Topics: Adolescent; Antifibrinolytic Agents; Bernard-Soulier Syndrome; Comorbidity; Deamino Arginine Vasopre | 2007 |
Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Adult; Aged; Aged, 80 a | 2007 |
A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene.
Topics: Angioedema; Antifibrinolytic Agents; Complement C1 Inhibitor Protein; Female; Humans; Pregnancy; Pre | 2007 |
Does drug therapy prevent recurrent bleeding from peptic ulcers?
Topics: Histamine H2 Antagonists; Humans; Peptic Ulcer Hemorrhage; Recurrence; Tranexamic Acid | 1984 |
Ruptured intracranial aneurysms: has the incidence of early rebleeding been over-estimated?
Topics: Cerebral Angiography; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Middle Aged; Recurr | 1982 |
The effect of tranexamic acid on secondary haemorrhage after traumatic hyphaema.
Topics: Adolescent; Adult; Anterior Chamber; Cyclohexanecarboxylic Acids; Female; Follow-Up Studies; Humans; | 1980 |
Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?
Topics: Brain Neoplasms; Fibrin Fibrinogen Degradation Products; Hemangioma; Humans; Intracranial Aneurysm; | 1980 |
Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity.
Topics: Aminocaproic Acid; Cyclohexanecarboxylic Acids; Fibrin Fibrinogen Degradation Products; Humans; Intr | 1980 |
Traumatic hyphaema treated ambulatory and without antifibrinolytic drugs.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Child; Child, Preschool; Eye Injuries; Female; Humans; Hyp | 1980 |
Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study.
Topics: Adolescent; Adult; Aged; Aminocaproates; Child; Cyclohexanecarboxylic Acids; Humans; Intracranial An | 1981 |
Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid.
Topics: Antifibrinolytic Agents; Bronchial Arteries; Child; Cystic Fibrosis; Embolization, Therapeutic; Fema | 1996 |
Major hemoptysis in a child with cystic fibrosis from multiple aberrant bronchial arteries treated with tranexamic acid.
Topics: Adolescent; Antifibrinolytic Agents; Bronchial Arteries; Combined Modality Therapy; Cystic Fibrosis; | 1996 |
Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency.
Topics: Aged; Anabolic Agents; Angioedema; Antifibrinolytic Agents; Aprotinin; Autoimmune Diseases; Calcium | 1997 |
Antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Humans; Recurrence; Subarachnoid Hemorrhage; Tranexamic | 1997 |
Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Female; Hemorrhage; Humans; Hydrocephalus; Int | 1998 |
[Patient with recurrent gastrointestinal hemorrhage in acquired von Willebrand disease].
Topics: Autoantibodies; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; Recurrence; Tranexamic Aci | 1999 |
[Hereditary angioneurotic edema in children].
Topics: Adolescent; Angioedema; Child; Child, Preschool; Complement C1 Inactivator Proteins; Danazol; Diagno | 2000 |
Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid.
Topics: Adult; Cystic Fibrosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemoptysis; Hum | 2001 |
Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
Topics: Angiodysplasia; Blood Transfusion; Combined Modality Therapy; Deamino Arginine Vasopressin; Estrogen | 2001 |
Recurrent abruptio placentae treated with the fibrinolytic inhibitor tranexamic acid.
Topics: Abruptio Placentae; Cyclohexanecarboxylic Acids; Female; Humans; Pregnancy; Recurrence; Tranexamic A | 1978 |
Response of "idiopathic" recurrent angioneurotic oedema to tranexamic acid.
Topics: Adult; Angioedema; Cyclohexanecarboxylic Acids; Female; Humans; Recurrence; Tranexamic Acid | 1978 |
Proceedings: Preoperative management of patients with aneurysmal subarachnoid haemorrhage. A preliminary comparative study of consecutive and randomized series.
Topics: Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Recurrence; Subarachnoid Hemorrhage; Tra | 1975 |
[Clinical study on rebleeding of cerebral anuerysms--with special references to the warning signs of rebleeding and antifibrinolytic treatment during waiting time for surgery (author's transl)].
Topics: Adult; Age Factors; Aged; Blood Pressure; Female; Humans; Hypnotics and Sedatives; Intracranial Aneu | 1975 |
Oral administration of tranexamic acid in the management of traumatic hyphema in children.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Eye Injuries; Female; Humans; Hyphema; In | 1992 |
Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms.
Topics: Adult; Aprotinin; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1987 |
Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage.
Topics: Cerebral Angiography; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneurysm; Prospective Studie | 1989 |
Problems in the use of tranexamic acid by ophthalmologists.
Topics: Cyclohexanecarboxylic Acids; Eye Diseases; Humans; Hyphema; Malpractice; Recurrence; Tranexamic Acid | 1989 |
Upper gastrointestinal bleeding: the trials of trials.
Topics: Clinical Trials as Topic; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Peptic Ulce | 1985 |
[Drug administration schedule of anti-ulcer agents to prevent recurrence of peptic ulcer; administration of synergistic drugs for protective factors in peptic ulcer--criteria of drug selection according to clinical symptoms and administration methods].
Topics: Anti-Ulcer Agents; Cyclohexanecarboxylic Acids; Diterpenes; Gefarnate; Humans; Peptic Ulcer; Recurre | 1988 |
[Drug administration schedule of anti-ulcer agents to prevent recurrence of peptic ulcer; combination therapy of inhibitors of attacking factors and synergistic drugs for protective factors in peptic ulcer--selection of drug combinations and clinical effi
Topics: Anti-Ulcer Agents; Cimetidine; Drug Administration Schedule; Drug Therapy, Combination; Gefarnate; H | 1988 |
[Comparative studies on recurrence and relapse rate in peptic ulcer treated with various types of anti-ulcer agent; synergistic drugs for protective factors in peptic ulcer].
Topics: Age Factors; Aged; Cyclohexanecarboxylic Acids; Humans; Peptic Ulcer; Recurrence; Sucralfate; Tranex | 1988 |
Management of traumatic hyphema in children. An analysis of 340 cases.
Topics: Bed Rest; Cataract; Child; Eye Injuries; Female; Humans; Hyphema; Hypnotics and Sedatives; Male; Occ | 1988 |
Antifibrinolytic therapy in the treatment of aneurysmal subarachnoid hemorrhage.
Topics: 4-Aminobenzoic Acid; Aminocaproates; Antifibrinolytic Agents; Humans; Intracranial Aneurysm; para-Am | 1986 |